CNS cancer articles from across Nature Portfolio

CNS cancer is a type of cancer that forms in the central nervous system. It includes brain stem glioma, craniopharyngioma, medulloblastoma and meningioma.

Featured

Latest Research and Reviews

News and Comment

  • News & Views |

    An artificial intelligence-based tool can turn low-resolution clinical MRI scans into high-resolution 3D objects suitable for research studies. The new approach opens up the possibility of secondary analysis of large clinical MRI datasets to answer disease-relevant questions, although further work to automate scan annotation will be required.

    • Giovanni B. Frisoni
  • News & Views |

    Using an unbiased algorithm based on kinase–phosphorylation site interactions that is applicable to any proteomic dataset, we identified and experimentally validated two protein kinases (PKCδ and DNA-PKcs) as the master kinases that drive two functional subtypes of glioblastoma multiforme and are potential therapeutic targets of other cancer subtypes.

    Nature Cancer 4, 159-160
  • News & Views |

    An ependymoma subtype is driven by fusion proteins related to the transcriptional regulator YAP1. Research now shows that localization of these fusion proteins within nuclear condensates is necessary and sufficient for tumour formation through the activation of various genetic and epigenetic oncogenic mechanisms.

    • Mahsa Shahidi Dadras
    •  & Howard A. Fine
    Nature Cell Biology 25, 211-213
  • News & Views |

    K27M mutation of histone H3 has been identified as a driver event in diffuse midline glioma. Two studies used comprehensive multi-model single-cell genomic, epigenomic and chromatin structure analysis to characterize the cell of origin and find a distinct etiology of H3K27M between pontine and thalamic tumors, and show that pontine gliomas harbor more immature oligodendrocyte-precursor-like cells.

    • Xiao-Nan Li
    Nature Genetics 54, 1770-1771
  • News & Views |

    Immunovirotherapy is a promising therapeutic strategy for glioblastoma (GBM), a deadly tumor for which effective treatments remain a clinical need. A new study describes an oncolytic herpes simplex virus (oHSV) armed with a bispecific anti-EGFR–CCL5 fusion protein that activates innate and adaptive antitumor immune responses that are highly efficacious in preclinical GBM models.

    • Judit Sanchez Gil
    •  & Samuel D. Rabkin
    Nature Cancer 3, 1274-1276